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Background: Gefitinib, an EGFR-tyrosine kinase inhibitor, significantly improve prognosis in patients with advanced
non-small cell lung cancer (NSCLC). The aim of this study was to evaluate the usefulness of MUC1 and vascular
endothelial growth factor (VEGF) mRNA expression in peripheral blood as means of predicting benefit from gefitinib
therapy in NSCLC patients.
Methods: MUC1 and VEGF mRNA expressions were detected in peripheral blood of 66 patients with advanced
NSCLC before (B0) and 4 weeks after treatment (B4w) with gefitinib, using real-time quantitative-PCR assay. Correlations
between blood MUC1 and VEGF mRNA expression at B0 and B4w and the response to gefitinib treatment and survival
were analyzed.
Results: Blood levels of MUC1 and VEGF mRNA at B0 and at B4w were significantly higher in patients with progressive
disease than in those with partial response and stable disease. Furthermore, blood MUC1 and VEGF mRNA positivity
at two time points were strongly associated with shorter progression-free survival (PFS) and overall survival (OS)
(P = 0.005 and P = 0.008 at B0, and P < 0.001 and P = 0.001 at B4w, respectively, for MUC1; P = 0.004 and P = 0.009 at B0,
and P = 0.001 and P < 0.001 at B4w, respectively, for VEGF). Multivariate analyses demonstrated that blood MUC1 and
VEGF mRNA positivity at B0 and B4w were independent factors for predicting worse PFS and OS.
Conclusions: MUC1 and VEGF mRNA positivity in blood seem to be indicators of unfavorable response and poor PFS
and OS in patients with advanced NSCLC treated with gefitinib and may be promising noninvasive and repeatable
markers for predicting efficacy of gefitinib treatment.
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SurvivalBackground
Lung cancer is the leading cause of cancer death world-
wide and it is responsible for more than 1 million deaths
annually [1]. Almost 85% lung cancer can be classified
as non-small cell lung cancer (NSCLC), with 65% to 75%
of case presenting as locally advanced (stage III) or
metastatic disease (stage IV) [2,3]. Chemotherapy is as-
sociated with modest survival benefit and improved* Correspondence: lijian541226@163.com
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unless otherwise stated.quality of life [4,5]; however, its efficacy has clearly
reached a plateau, and thus further improvements will
require integration of novel therapies. Among the target
agents, epidermal growth factor receptor (EGFR) inhibi-
tors gefitinib and erlotinib are now established as an op-
tion for first-, second- or third-line treatment, or as
maintenance treatment [6-11].
Considerable research has been undertaken to identify
molecular markers that predict sensitivity to EGFR-tyrosine
kinas inhibitors (TKIs). On the basis of the data from clin-
ical trials comparing EGFR-TKIs with placebo or chemo-
therapy, EGFR-activating mutation status appears to be thehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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would derive the most benefit from EGFR-TKI treat-
ment [7-9,12-14]. Nevertheless, the clinical efficacies
of EGFR-TKIs differ among such patients, and almost
all individuals eventually develop resistance to these
drugs. Moreover, clinical studies have also shown that
even in patients with wild-type EGFR, EGFR-TKIs are
either superior to placebo or not inferior to docetaxel
chemotherapy as a second- or third-line therapy [9,10].
To date, no effective biomarker is currently available for
patients with wild-type EGFR tumor [15]. In addition, it is
sometimes difficult to obtain sufficient tumor samples
from patients with inoperable NSCLC for mutation ana-
lysis. Hence, practical clinical studies using blood markers
that can predict treatment efficacy of NSCLC to EGFR-
TKIs are urgently required.
Some studies have reported that serum levels of
MUC1 (mucin 1, also called KL-6) and vascular
endothelial growth factor (VEGF) are associated with
tumor response, progression-free survival (PFS) and
overall survival (OS) in NSCLC patients treated with
EGFR-TKIs [16,17]. Blood samples can be obtained
safely, with the option of repeat sampling from all
NSCLC patients regardless of patient characteristics.
In this report, we prospectively studied the expression
levels of MUC1 and VEGF mRNA in peripheral blood
of patients with advanced NSCLC who underwent
treatment with gefitinib. The aim of this study was to
identify whether there are correlation between MUC1
and VEGF mRNA levels in blood of these patients and




In this prospective study, patients aged ≥20 years with
histologically confirmed stage IIIB or IV NSCLC in
whom one or two prior chemotherapy regimen had
failed or who were unsuitable or unwilling to undergo
such chemotherapy were eligible for study inclusion. Pa-
tients were required to have tumor tissue accessible for
tissue sampling by bronchoscopy, or lymph node biopsy
(metastatic sites), or surgery; clinically measurable dis-
ease; performance status (PS, according to the criteria of
Eastern Cooperative Oncology Group) of 0 to 3; ad-
equate bone borrow, renal and hepatic function and an
interval of ≥4 weeks since previous surgery or radiother-
apy. All patients received gefitinib 250 mg orally once a
day until disease progression, patient refusal, or develop-
ment of intolerable toxicity, or death. This study was per-
formed in accordance with the Declaration of Helsinki and
has been approved by the ethic committee of Affiliated
Hospital of Jiangsu University in China. Written informed
consent was obtained from all participants.Study design
All patients had a pretreatment tumor assessment by
computerized tomography (CT) scan, which was re-
peated to assess tumor response after a maximum of
8 weeks from the beginning of the treatment, then every
2 months until 9th month, and every 4 months there-
after. Tumor response was evaluated using the criteria
of RECIST [18], classified as a complete response (CR), a
partial response (PR), stable disease (SD), or progressive
disease (PD). CR and PR were defined as the objective
response. Disease control was judged when patients
achieved the best response of CR, PR, or SD, which was
confirmed and sustained for 6 weeks.
Specimen collection
For all NSCLC patients, blood specimens were collected
within one week prior to (B0) and 4 weeks after the start
of gefitinib administration (B4w). Meanwhile, blood
samples of 55 patients with benign lung disease (BLD)
were used as controls. BLD included chronic obstructive
pulmonary disease (18), asthma (14), pneumonia (12),
interstitial lung disease (6), tuberculous pleurisy (5).
Approximately 6 mL peripheral blood from all of the
subjects was collected into EDTA-containing tubes,
stored at 4°C, and processed within two hours. The first
4 mL of peripheral blood collected were discarded to
avoid contamination with skin epithelial cells. Peripheral
blood mononuclear cells (PBMCs) were firstly isolated
by density centrifugation (1500 rpm for 15 min) with
lymphocyte separation medium and washed with PBS
(1200 rpm for 10 min), cell pellet were suspended in
1 mL of Isogen (Nippon Gene, Toyama, Japan) and were
stored at −80°C until use.
RNA isolated and real-time quantitative-PCR
Total RNA was extracted by the guanidium-
isothiocyanatephenol-chloroform-based method. The
purity and quality of the RNA were measured by UV-
visible spectrophotometer (Bio-Tek); 2% agarose gel
electrophoresis and ethidium bromide staining were
used to assess the integrity of the obtained RNA. First-
strand cDNA was produced from total RNA by using
an RNA PCR kit version 3.0 (TakaRa Bio Inc., Tokyo,
Japan), according to manufacturer’s instruction.
The real-time quantitative (RTQ)-PCR of MUC1 and
VEGF gene and β-actin as internal control was carried
out on an ABI 7500 thermal cycler Real-time PCR sys-
tem (Applied Biosystems, Foster Cyty, CA, USA), using
the SYBR-Green I chemistry. Amplification primers of
the three genes were synthesized by BioAsia Corporation
(Shanghai, China) as follows: primer sequences for MUC1
were 5’AATGAATGGCTCAAAACTTGG3’ and 5’CAC
TAGGTTCTCACTCGCTCAG3’ and for VEGF, 5’GAG
TACATCTTCAAGCCATCCTG3’ and 5’TGCTCTATCT
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CATCCGCAAAG3’ and 5’CTGGAAGGTGGACAGCG
AGG3’. The cycling conditions have been described in de-
tail in previous report [19]. Detection of PCR products
was accomplished by measuring the emitting fluorescence
(Rn) at the end of each reaction step. Threshold cycle (Ct)
correspond with the cycle number required to detect a
fluorescence signal above the baseline.
Relative quantification was calculated with the Ct
(2—△△Ct) method [20]. Each experiment was performed
in triplicate. The average value of the replicates was
used as quantitative value for each sample.
Detection of EGFR mutation
One tumor biopsy or surgery sample from each patient
was snap frozen immediately in liquid nitrogen. DNA
was extracted from tissue samples containing more than
70% tumor cells using the QIAamp DNA Mini kit
(Qiagen, Hilden, Germany). EGFR mutations in exon 18
to 21 were detected by PCR based direct sequencing re-
ported previously [21]. The primers used and amplifica-
tion condition have been described in detail [21]. PCR
products were 2% gel-purified with a QIA gen gel
extraction kit (Qiagen). DNA templates were processed
for the DNA sequencing reaction using the ABI-PRISM
Big Dye Terminator version 3.1 (Applied Biosystems,
Foster Cyty, CA) with both forward and reverse sequence-
specific primer according to the manufacturer’s guidelines.
Sequence data were generated with the ABI PRISM 3100
DNA Analyzer (Applied Biosystems). Sequences were ana-
lyzed by Sequencer 3.1.1 software (Applied Biosystems) to
compare variations.
Statistical analysis
Blood MUC1 and VEGF mRAN levels are presented as
median (range) because they were not normally distrib-
utes. Differences in the levels of both markers before
treatment compared with 4 weeks after treatment and
differences in patients with a PR or SD compared with
those with PD were analyzed by Mann–Whitney test.
The relation between MUC1 and VEGF mRNA levels
was assessed using the spearman correlation coefficient.
Associations between MUC1 or VEGF mRNA positivity
and clinicopathologic factors including response to treat-
ment were examined by Fisher’s exact tests. PFS was de-
fined as the interval between the start of gefitinib
therapy and the first manifestation of PD or death from
any cause. OS was defined as the interval between the
start of gefitinib therapy and death from any cause. The
survival curves for PFS and OS were estimated using the
Kaplan-Meier method, and differences between the two
groups were compared with the log-rank tests. Multi-
variate Cox proportional hazard model was applied to
examine whether the positive expressions of MUC1 orVEGF mRNA in blood were associated with PFS of OS
even after adjustment for other prognostic factors. All
tests were two sided, and P value <0.05 was considered
statistically significant.
Results
Patient characteristics and treatment response
A total of 66 patients were enrolled this study. The pa-
tient characteristics are shown in Table 1. Twenty nine
(43.9%) patients were female and 22 (33.3%) were never-
smokers, with the median age of all patients being
67 years (range, 42–79 years). Thirty nine (59.1%) had
adenocarcinoma, 52(78.8%) had PS 0–1, and 20 patients
(30.3%) received gefitinib as first-line therapy. A total of
60 tumor samples were suitable for EGFR mutation ana-
lysis. EGFR mutations were identified in 22 (33.3%) of
the 60 patients, 14 patients had deletions mutations in
exon 19 and 8 patients had the point mutations in exon
21 (L858R). The results for response to gefitinib showed
that 25 patients (37.9%) achieved a PR, and 20 (30.3%)
had SD. The other 21 patients (31.8%) had PD. The
response rate (PR) was 37.9%, the disease control rate
(PR + SD) was 68.2%. Regarding association between
treatment response and clinicopathologic factor, female
gender (P = 0.007), adenocarcinoma histology (P = 0.004)
and an EGFR mutation status (P = 0.005) were signifi-
cantly associated with disease control rate achieved by
gefitinib treatment (Table 1). In addition, adenocarcin-
oma (P = 0.022) and EGFR mutation (P = 0.018) were
significantly associated with the responsiveness to
gefitinib, but no association was found between other
clinicopathologic factors and the response to gefitinib
therapy (Table 1).
Analyses of MUC1 and VEGF mRNA levels in blood
specimens of NSCLC patients
The blood levels of MUC1 and VEGF mRNA in NSCLC
patients before (B0) and 4 weeks after gefitinib treatment
(B4w) were significantly higher than in BLD patients
(Table 2). Moreover, the blood levels of MUC1 and VEGF
mRNA markedly decreased after treatment (Table 2).
Meanwhile, a correlation was found between MUC1 and
VEGF mRNA levels in blood sample (spearman correl-
ation analysis: rs = 0.538, P = 0.003).
Figure 1 shows associations between the blood levels
of MUC1 and VEGF mRNA and response to treatment.
At B0 and B4w time points, MUC1 and VEGF mRNA
levels in patients with PR or SD were significantly lower
than those in patients with PD (PR vs PD, P = 0.003; SD
vs PD, P = 0.005, respectively at B0; PR vs PD, P = 0.004;
SD vs PD, P = 0.006, respectively at B4w) (Figure 1A
and B). Similarly, VEGF mRNA levels at two time points
were significantly lower among patients with PR or SD
than among those with PD (PR vs PD, P = 0.005; SD vs
Table 1 Associations between patient clinicopathologic factors and response to gefitinib
Variable Total (n = 66)
(%)
Response to gefitinib treatment
PR (N = 25) SD (n = 20) PD (n = 21) P value (PR vs SD + DP) P value (PR + SD vs PD)
Sex
Male 37(56.1) 11 9 17 0.136 0.007
Female 29(43.9) 14 11 4
Age, yr
<67 34(51.5) 11 11 12 0.447 0.603
≥67 32(48.5) 14 9 9
Smoking history
Never 22(33.3) 11 7 4 0.187 0.112
Former 18(27.3) 6 5 7
Current 26(39.4) 8 8 10
Histology
ADC 39(59.1) 20 12 7 0.022 0.004
SCC 22(33.3) 4 6 12
ASC 5(7.6) 1 2 2
Performance status
0-1 52(78.8) 19 16 17 0.760 0.421
2-3 14(21.2) 6 4 6
Disease stage
IIIB 10(15.2) 5 2 3 0.729 0.945
IV 56(84.8) 22 16 18
Prior chemotherapy
Yes 46(69.7) 18 16 12 0.790 0.157
No 20(30.3) 7 4 9
EGFR status
Wild-type 38(57.6) 9 11 18 0.018 0.005
Mutation 22(33.3) 12 8 2
Unknown 6(9.1) 4 1 1
MUC1 mRNA at B0
Median 5.95 4.87 5.18 8.76 0.116 0.005
Range 1.16-17.56 1.16-8.75 2.45-10.73 2.24-17.56
VEGF mRNA at B0
Median 4.88 4.21 4.72 7.65 0.122 0.004
Range 1.07-15.32 1.07-9.86 1.62-10.24 2.31-15.32
PR, partial response; SD, stable disease; PD, progressive disease; ADC, adenocarcinoma; SCC, squamous cell carcinoma; ASC, adenosquamous cell carcinoma.
Table 2 Blood levels of MUC1 and VEGF mRNA in NSCLC patients and BLD patients at two sampling time points




valueMedian Range Median Range Median Range Median Range
NSCLC 66 5.95 1.16-17.56 4.46 0.64-12.45 0.027 4.88 1.07-15.32 3.82 0.88-13.84 0.035
BLD 55 2.06 0.32-4.17 1.75 0.41-3.28
P value <0.001 0.002* <0.001 0.003*
*NSCLC patients at B4w compared with BLD patients.
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Figure 1 MUC1 and VEGF mRNA levels in blood of NSCLC patients. (A and B) Box-whisker plots of blood MUC1 mRNA levels in NSCLC
patients with progressive disease (PD), stable disease (SD) and partial response (PR) before (B0) and 4 weeks after the start of gefitinib treatment
(B4w). (C and D) Box-whisker plots of blood VEGF mRNA levels in NSCLC patients with PD, SD and PR at B0 and B4w.
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vs PD, P = 0.004, respectively at B4w) (Figure 1C and D).
No difference was observed in the levels of MUC1 and
VEGF mRNA between patients with PR and those with SD.
Figure 2 shows the changes in blood levels of MUC1
and VEGF mRNA in patients with PR, or SD, or PD, be-
fore and 4 weeks after gefitinib treatment. In the patients
with PR, MUC1 and VEGF mRNA levels at B4w were
significantly lower as compared with those at B0 time
point (P = 0.009 and P = 0.010, respectively) (Figure 2A
and D). In patients with SD, MUC1 and EVGF mRNA
levels at D4w were marginally lower than those at B0
(P = 0.062 and P = 0.078, respectively) (Figure 2B and E).
In the patients with PD, however, the two marker mRNA
levels at B4w were significantly higher than those at B0
(P = 0.023 and P = 0.038, respectively) (Figure 2C and F)Association between MUC1 and VEGF mRNA positivity
and clinicopathologic factors
The maximum values of MUC1 and VEGF mRNA in
BLD patients were 4.17 and 3.28 respectively (Table 2).
Thus, the cutoff values of 4.2 and 3.3 were used as posi-
tive threshold for MUC1 and VEGF mRNA respectively.
The blood samples were regarded as MUC1 or VEGF
mRNA positivity if MUC1 and VEGF mRNA level above
the two cutoff values respectively. Using the two cutoff
values, 75.8% (50/66) and 45.5% (30/66) of B0 and B4w
blood samples were considered MUC1 mRNA positivity;
71.2% (47/66) and 43.9% (29/66) of B0 and B4w blood
samples were considered VEGF mRNA positivity, respect-
ively. The positive rates of the two markers were signifi-
cantly lower at B4w as compared with at B0 (P = 0.001
and P = 0.003, respectively).
Figure 2 Changes of MUC1 and VEGF mRNA levels in blood of NSCLC patients. (A to C) Changes of MUC1 mRNA levels between before
(B0) and 4 weeks after gefitinib treatment (B4w) in blood of NSCLC patients with partial response (PR), stable disease (SD) and progressive disease
(PD). (D to F) Changes in blood VEGF mRNA levels between B0 and B4w time points in NSCLC patients with PR, SD and PD.
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MUC1 and VEGF mRNA positivity at B0 and B4w and
clinicopathologic factors. As shown in Table 3, hist-
ology (P = 0.045 and P = 0.024, respectively) and the
response to gefitinib treatment (P = 0.013 and P =
0.002, respectively) were significantly associated with
MUC1 mRNA positivity at B0 and B4w. Similarly, the
associations were found between the VEGF mRNA
positivity at two sampling time points and histology
(P = 0.053 and P = 0.013, respectively) and response to
gefitinib treatment (P = 0.025 and P = 0.018, respect-
ively). In addition, EGFR mutation status seems to be
associated with MUC1 or VEGF mRNA positivity,
even though these differences were borderline statisti-
cally significant (Table 3). No association was found
between the MUC1 or VEGF mRNA positivity and
other clinicopathologic factors.Correlation between MUC1 and VEGF mRNA positivity
and PFS and OS
Survival was analyzed in the all 66 patients, the median
follow-up time was 11.2 months [95% confidence inter-
val (CI): 8.4-16.6]. At the time of analysis, 48 patients
had died and 18 patients had survived. For the entire
patient population, the median PFS and OS were
5.2 months (95% CI: 2.6-8.9) and 10.8 months (95% CI:
7.3-15.2) respectively. Patients with blood MUC1 mRNA
positivity at B0 and B4w proved to have significantly
shorter median PFS and OS when compared with
patients presenting with blood MUC1 mRNA negativity
(P = 0.005 and P = 0.008, respectively at B0; and P <
0.001 and P = 0.001, respectively at B4w; Figure 3A
and B). The similar results were found in patients with
VEGF mRNA positivity and negativity at two sampling
time points (P = 0.004 and P = 0.009, respectively at D0;
Table 3 Associations between MUC1 or VEGF mRNA positivity and clinicopathologic factors
MUC1 mRNA VEGF mRNA
















Male 27 10 16 21 25 12 17 20
Female 23 6 14 15 22 7 12 17
P value 0.579 0.804 0.586 0.805
Smoking history
Never 15 7 7 15 13 9 7 15
Non-never 35 9 23 21 34 10 22 22
P value 0.225 0.121 0.156 0.168
Histology
ADC 26 13 13 26 24 15 12 27
Non-ADC 24 3 17 10 23 4 17 10
P value 0.045 0.024 0.053 0.013
Performance status
0-1 40 12 22 30 36 16 22 30
2-3 10 4 8 6 11 3 7 7
P value 0.730 0.375 0.741 0.763
Disease stage
IIIB 7 3 6 4 5 5 6 4
IV 43 13 24 32 42 14 23 33
P value 0.695 0.814 0.248 0.437
EGFR status
Wild-type 32 6 21 17 31 7 21 17
Mutation 13 9 6 16 12 10 7 15
Unknown 5 1 3 3 4 2 1 5
P value 0.083 0.102 0.058 0.095
Tumor response
PR 14 11 7 18 13 12 8 17
SD 17 3 7 13 16 4 6 14
PD 19 2 16 5 18 3 15 6
P value 0.013 0.002 0.025 0.018
ADC, adenocarcinoma; PR, partial response; SD, stable disease; PD, progression disease.
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and D).
Univariate analysis showed that adenocarcinoma hist-
ology, EGFR mutations, and blood MUC1 and VEGF
mRNA positivity were associated with PFS. PS, disease
stage, adenocareinoma histology, EGFR mutations and
the two marker positivity were associated with OS. A
multivariate Cox proportional hazard model for PFS and
OS was built using the variables that were found signifi-
cant at the univariate analysis. Blood MUC1 and VEGF
mRNA positivity at two sampling time points and EGFR
mutation were independent predictors of shorter PFS(Table 4). Furthermore, blood MUC1 and VEGF mRNA
positivity, PS and EGFR mutation were independent
predictors of wore OS (Table 4).
Discussion
Several markers have been identified that predict response
to the EGFR-TKIs in NSCLC patients. Among them,
EGFR mutation status was found to be the strongest pre-
dictive marker for the response to EGFR-TKIs and survival
[7-9,12-14]. Meanwhile, emerging data suggest that resist-
ance to EGFR-TKIs may be also due to the activation of
protein downstream of the receptor (K-RAS, mitogen-
Figure 3 Kaplan-Meier curves of progression-free survival (PFS) and overall survival (OS). (A and B) PFS and OS curves according to the
positivity or the negativity of MUC1 mRNA in blood of NSCLC patients before (B0) and 4 weeks after the start of treatment (B4w). (C and D) PFS
and OS curves according to the positivity or the negativity of VEGF mRNA in blood of NSCLC patients at B0 and B4w time points.
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Table 4 Multivariate Cox proportional hazard model analysis of PFS and OS
Variable Progression-free survival Overall survival
Hazard ratio 95% CI P value Hazard ratio 95% CI P value
Histology
ADC vs non-ADC 1.154 0.637-2.622 0.255 1.118 0.563-2.527 0.248
Performance status
0-1 vs 2-3 1.845 1.052-2.995 0.114 2.532 1.219-4.325 0.013
Disease stage
IIIB vs IV 0.875 0.317-2.152 0.416 1.272 0.428-2.257 0.167
EGFR status
Wild-type vs mutation 2.726 1.415-4.655 0.011 2.615 1.338-4.524 0.014
MUC1 mRNA at B0
Positivity vs negativity 2.359 1.155-4.326 0.018 2.494 1.536-4.721 0.015
MUC1 mRNA at B4w
Positivity vs negativity 2.855 1.512-4.779 0.007 2.842 1.975-5.013 0.009
VEGF mRNA at B0
Positivity vs negativity 2.453 1.415-4.592 0.013 2.577 1.482-4.683 0.011
VEGF mRNA at B4w
Positivity vs negativity 3.012 2.103-5.148 0.004 2.910 1.971-5.106 0.006
ADC, adenocarcinoma.
Li et al. BMC Cancer 2014, 14:848 Page 9 of 11
http://www.biomedcentral.com/1471-2407/14/848activated protein kinase, and signal transducers and activa-
tors of transcription 3), epithelial-mesenchymal transition
of tumor cells, and other cell surface proteins, such as
cMET [22-26]. Nevertheless, all these changes do not
completely explain the variable clinical outcomes, and
identification of other biomarkers of EGFR-TKI sensitiv-
ity/resistance may help in optimal patient selection.
Previous studies have reported significant associations
between serum MUC1 and VEGF levels and tumor re-
sponse, PFS and OS in patients with advanced NSCLC
treated with EGFR-TKIs [16,17]. By using the highly
sensitive RTQ-PCR assay in a representative series of
NSCLC patients, we demonstrate that detections of
MUC1 and VEGF mRNA in peripheral blood are valu-
able diagnostic tools to identify a subset of NSCLC
patients who benefit from gefitinib treatment.
MUC1 is a cell surface glycoprotein and aberrantly
overexpressed in various carcinomas of epithelial origin
including NSCLC, and induce gene signatures that are
associated with poor survival of NSCLC patients [27].
MUC1 is translated as a single polypeptide that under-
goes autocleavege into MUC1-N and MUC1-C subunits.
MUC1-C is a transmembrane protein that functions as a
cell surface receptor [28]. The MUC1-C extracellular do-
main interacts with ligand galectin-3 and thereby forms
complexes with EGFR [28]. The available evidence indi-
cates that MUC1-C is a binding partner and a substrate
of EGFR, and it expression can promote EGFR-mediated
signaling, while also enhancing EGFR stability by inhibit-
ing its down-regulation upon EGFR stimulation [29,30]. Inaddition, MUC1-C activates the phosphatidylinositol3-
kinase (PI3K)-Akt pathway and the MUC1-C cytoplasmic
domain has an YHPM site that following phosphorylation
functions as a binding site for the PI3K SHZ domain [31].
Some studies have indicated that effective treatment of
NSCLC cells with EGFR inhibitors is associated with sup-
pression of PI3K activity and resistance to these inhibitors
occurs with reactivation of the PI3K-Akt signaling path-
way [32]. Overexpression of MUC1 as found in human
carcinomas is associated with accumulation of MUC1-C
in cytoplasm and targeting of MUC1-C to the nucleus
[27]. Although the exact role of blood MUC1 in develop-
ment and progression of NSCLC has not been completely
illuminated, these findings suggest that MUC1 can influ-
ence EGFR signaling directly by binding with EGFR or
indirectly through it interaction with PI3K-Art pathway,
regulating the clinical efficacy of EGFR-TKI treatment.
In the present study, we show that blood levels of
MUC1 mRNA were dramatically decreased during EGFR-
TKI treatment. But blood MUC1 mRNA remained posi-
tivity in 45.5% of these NSCLC patients at 4 weeks
after EGFR-TKI treatment. Moreover, the blood levels of
MUC1 mRNA during treatment were significantly in-
creased in patients with tumor response of PD, whereas
the patients who achieved a PR had a significant decrease
in blood MUC1 mRNA levels, implying that the changes
of MUC1 mRNA levels in the course of treatment with
gefitinib may predict imaging response to treatment. Fur-
thermore, the positivity of blood MUC1 mRNA before and
during EGFR-TKI treatment were significantly associated
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by multivariate analysis. Our results were in line with the
study by Ishikawa et al. and showed that blood MUC1
detection could be used as a marker to predict the efficacy of
gefitinib treatment in patients with advanced NSCLC [16].
VEGF is a critical proangiogenic factor in tumor and
promotes endothelial cell growth, survival, and migra-
tion and mediates vessel permeability, thereby facilitating
tumor progression and metastatic spread [33]. The
VEGF and EGFR pathway are closely related, sharing
common down-stream signaling pathway [34]. EGF and
transforming growth factor-α both induce VEGF expres-
sion via activation of EGFR in cell culture models and
have proangiogenic properties. EGFR pathway modulates
angiogenesis by up-regulating VEGF or other key media-
tors in angiogenic process [34]. In preclinical models,
EGFR blockade with the monoclonal antibody cetuximab
resulted in down-regulation of proangiogenic mediators,
including VEGF, accompanied by reductions in micro-
vessel density and metastasis [35]. On the basis of these
data, we hypothesize that blood VEGF mRNA levels
have the potential to be a predictive marker of clinical
benefit in patients with advanced NSCLC treatment with
EGFR-TKIs.
In the present study, we showed that the positivity of
VEGF mRNA in blood samples detected by the RTQ-
PCR assay was correlated statistically with responsive-
ness to, and the PFS and OS of, gefitinib treatment.
Moreover, our study have also shown a relationship be-
tween the changes of VEGF mRNA levels on the course
of gefitinib treatment and imaging response, which is
similar to association between the changes of MUC1
mRNA levels and imaging response to gefitinib.
In the study by Kasahar et al. [17], the pretreatment
serum VEGF levels were measured in 95 patients with
lung adenocarcinoma who received EGFR-TKI treat-
ment, although patients presenting with a higher serum
VEGF levels proved to have a poor tumor response,
significantly shorter PFS and OS than patients with
lower serum VEGF levels, these features did not inde-
pendently determine OS in multivariate analysis. A pos-
sible reason of the discrepancy between the study by
Kasahar et al. and our study may be due to different
method of VEGF detection. Kasahar et al. used enzyme-
linked immunosorbent assay (ELISA) to measure serum
VEGF levels, while we applied RTQ-PCR technique to
detect blood VEGF mRNA expression. We infer that
VEGF mRNA detected by RTQ-PCR was more sensitive
and accurate than serum VEGF level measured by ELISA.
We are aware of some limitations in the present study.
First, the total sample size is relatively small which may
result in some bias of result. Second, blood MUC1 and
VEGF mRNA levels detected at two sampling time
points did not be compared with CEA and CYFRA 21–1which generally recognized as two prognostic markers for
NSCLC. Third, detection of MUC1 and VEGF mRNA
using RTQ-PCR is relatively complicated in methodology
and experimental handle is time–consuming which may
influence routine use in clinical practice, although RTQ-
PCR is a highly sensitivity and specific analysis tool.
Conclusions
In summary, our results show that NSCLC patients with
positivity of blood MUC1 and VEGF mRNA seem to
have poor outcomes with gefitinib treatment, in terms of
PFS, OS and response, than those with negativity of the
two markers. These findings support the nation that the
detection of blood MUC1 and VEGF mRNA by RTQ-
PCR could to be used as biomarkers to predict treatment
efficacy of EGFR-TKIs in NSCLC patients. Further study
with large number of patient is warranted to clarify the
clinical utility of RTQ-PCR assay for MUC1 and VEGF
mRNA expression in blood sample in determination of
the optimal treatment for advanced NSCLC patients.
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